Exhibit 99.1



 MORRIS PLAINS, N.J., March 21, 2000 -- Warner-Lambert Company announced
 today that it is voluntarily discontinuing the sale of REZULIN
 (troglitazone) Tablets, its therapy for the treatment of type 2 diabetes,
 although the Company continues to believe that the benefits of the drug
 outweigh its associated risks.

      Patients taking REZULIN should consult with their physicians as soon
 as possible to discuss alternative therapies. Warner-Lambert will work
 closely with the Food and Drug Administration and other constituencies to
 assure a safe and efficient transition for patients as they switch to
 alternative therapies.

      The Company has always believed that it is essential for patients and
 physicians to receive accurate and objective information regarding the
 benefits and risks of REZULIN.  It was for this reason that Warner-Lambert
 requested a public meeting of the FDA's expert Advisory Committee. However,
 repeated media reports sensationalizing the risks associated with REZULIN
 therapy have created an environment in which patients and physicians are
 simply unable to make well-informed decisions regarding the safety and
 efficacy of REZULIN. Under these circumstances, and after discussions this
 evening with the FDA, we have decided it is in the best interests of
 patients to discontinue marketing REZULIN at this time.